-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

Benzinga·05/14/2026 17:15:49
Listen to the news
Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and raises the price target from $20 to $22.